Government officials in Guinea-Bissau have formally blocked a controversial clinical trial funded by the United States that proposed delaying the birth dose of the hepatitis B vaccine for thousands of newborns. Led by Danish researchers from the Bandim Health Project and the University of Southern Denmark, the study drew fierce condemnation from global health authorities and bioethicists who argued that withholding a proven, life-saving immunization from infants in a high-risk region violated fundamental medical ethics.

According to Ars Technica, lead researcher Christine Stabell Benn confirmed that Guinea-Bissau's Council of Ministers formally reaffirmed its non-acceptance of the study on October 16, 2026. The rejection was followed on October 19, 2026, by a judicial police raid on the Bandim Health Project's offices in Guinea-Bissau, where authorities seized hepatitis B vaccine doses intended for the research, according to The BMJ. While some media outlets described the trial as halted, reporting from The BMJ and The Epoch Times clarifies that the study never actually began, and no infants were enrolled or vaccinated before the government refused final authorization.

Why the Proposed Study Sparked International Backlash

At the center of the dispute was the trial's experimental design. As reported by The Hill and Blavity News & Entertainment, the protocol planned to enroll approximately 14,000 newborns in Guinea-Bissau and randomly assign half of them to receive the hepatitis B vaccine at birth, while the other half would wait six weeks before receiving their first dose.

Hepatitis B is a severe viral infection that attacks the liver and is frequently passed from mother to child during childbirth. According to Blavity News & Entertainment, when newborns contract the virus at birth, the infection becomes chronic in up to 90% of cases, placing those children at steep risk for liver failure, cirrhosis, and liver cancer later in life. Because of this immediate vulnerability, the World Health Organization (WHO) recommends that all infants receive their first hepatitis B vaccine dose as soon as possible after birth, ideally within 24 hours.

The researchers behind the Bandim Health Project—run by Stabell Benn and her husband, Peter Aaby—did not question whether the vaccine prevents liver infection. Instead, differing accounts highlight a sharp divide over the scientific rationale for the delay. According to Blavity News & Entertainment and MedicalBrief, the researchers aimed to investigate whether the birth dose carries "non-specific" effects on overall mortality, early neurodevelopment, and skin conditions, maintaining that all enrolled infants would still receive later vaccine doses. Conversely, Ars Technica notes that the WHO objected in February 2026, stating that the proposal relied on hypothetical safety outcomes without credible evidence to justify exposing newborns in a high-prevalence country to potentially irreversible harm.

US Funding and Conflicting Accounts of Approval

Public scrutiny intensified after the U.S. Centers for Disease Control and Prevention (CDC) awarded an unsolicited $1.6 million grant to the Bandim Health Project in December 2025. Paired with an additional $1.6 million from private philanthropic sources, the total proposed budget reached $3.2 million, according to Punch Newspapers.

As detailed by Ars Technica, Aaby and Stabell Benn's work on non-specific vaccine effects has previously drawn praise from vaccine critics, including U.S. Health Secretary Robert F. Kennedy Jr., while facing scrutiny from scientific peers and an ongoing investigation by Danish authorities into alleged scientific misconduct in earlier studies. In the United States, congressional Democrats on the House Committee on Energy and Commerce demanded answers from CDC leadership on October 22, 2026, questioning the agency's funding and ethical oversight of the project.

The cancellation also exposed conflicting reports regarding local regulatory clearance in West Africa. According to The Epoch Times, the researchers cited an approval letter from Guinea-Bissau's national ethics committee as well as ethics review clearance in Denmark. However, MedicalBrief reported that Guinea-Bissau's health minister stated the national government had never authorized the trial. Stabell Benn subsequently acknowledged to Ars Technica that while her team considered the study scientifically and ethically justified, they respected the government's authority to decide whether research may proceed.

What This Means for Global Research Standards

For parents and public health advocates, the dispute underscores a critical distinction: the controversy never involved doubts about the safety or efficacy of the hepatitis B vaccine itself. Decades of clinical data confirm that newborn immunization safely prevents chronic liver disease.

Instead, bioethicists point to the episode as a critical test of international research protections. As Blavity News & Entertainment reported, clinical protocols that deliberately withhold an established, standard-of-care birth vaccine would face immediate rejection from institutional review boards in the United States or Denmark. Furthermore, because systemic resource constraints in Guinea-Bissau mean routine birth doses are not yet universally available across all public maternity wards, critics warned that the study's consent model risked pressuring parents into enrolling their infants just to secure access to medical care.

Frequently Asked Questions

Why was the hepatitis B birth dose delay considered dangerous?

When hepatitis B is transmitted from mother to baby during birth, up to 90% of infected newborns develop a chronic, lifelong infection that can lead to cirrhosis and liver cancer. Administering the vaccine within 24 hours of birth is the global standard of care to prevent this transmission; delaying the dose by six weeks leaves infants unprotected during their most vulnerable window.

Did the trial enroll or harm any babies before it was stopped?

No. Although early media coverage referred to the study as halted, researchers and The BMJ confirmed that the trial never received final government authorization to begin, and no newborns were enrolled or vaccinated under the protocol.

What questions remain under investigation?

Following the October 19, 2026 police seizure of vaccine doses in Guinea-Bissau and inquiries from U.S. lawmakers, unresolved questions remain regarding how the CDC conducted its ethical review before awarding the $1.6 million grant, as well as the discrepancy between the ethics committee letter held by researchers and the national government's refusal to authorize the trial.

Sources